Clene Inc. (CLNN)
NASDAQ: CLNN · IEX Real-Time Price · USD
4.470
+0.140 (3.23%)
Jul 22, 2024, 11:25 AM EDT - Market open
Clene Employees
As of December 31, 2023, Clene had 85 total employees, including 82 full-time and 3 part-time employees. The number of employees decreased by 1 or -1.16% compared to the previous year.
Employees
85
Change (1Y)
-1
Growth (1Y)
-1.16%
Revenue / Employee
$7,294
Profits / Employee
-$574,282
Market Cap
28.31M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 85 | -1 | -1.16% |
| Dec 31, 2022 | 86 | -16 | -15.69% |
| Dec 31, 2021 | 102 | 28 | 37.84% |
| Dec 31, 2020 | 74 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Big Lots | 30,300 |
| Natural Alternatives International | 317 |
| Local Bounti | 301 |
| Four Seasons Education | 190 |
| Maison Solutions | 174 |
| Top Wealth Group Holding | 12 |
| Carmell Therapeutics | 10 |
CLNN News
- 10 days ago - Clene to Present at the Emerging Growth Conference - GlobeNewsWire
- 11 days ago - Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS - GlobeNewsWire
- 13 days ago - Clene Announces 1-for-20 Reverse Stock Split - GlobeNewsWire
- 4 weeks ago - Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference - GlobeNewsWire
- 4 weeks ago - Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome - GlobeNewsWire
- 4 weeks ago - Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting - GlobeNewsWire
- 7 weeks ago - Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP) - GlobeNewsWire
- 2 months ago - Clene to Present at Upcoming May Conferences - GlobeNewsWire